Tacrolimus prolongs graft survival

Article

Tacrolimus is relatively safe and effective in reducing rejection and prolonging graft survival in subjects with high-risk keratoplasty.

Tacrolimus is relatively safe and effective in reducing rejection and prolonging graft survival in subjects with high-risk keratoplasty, according to a study published in the January issue of the British Journal of Ophthalmology.

Harminder Dua and colleagues from the University of Nottingham, UK enrolled 43 subjects undergoing high-risk corneal transplantation to receive systemic tacrolimus. Tacrolimus, a specific T cell inhibitor, was used at a mean daily dose of 2.5 mg for immunosupression and this was continued for between 18 and 24 months after the graft.

During a mean follow-up period of 33.7 months, 65% of subjects maintained clarity of graft, while eight subjects experienced rejection episodes, which led to graft failure in five.

It was concluded that tacrolimus offers a relatively safe and effective method of sustaining graft survival.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.